The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q1 2018 call → NOWe need to determine if management conveys that the reported results for Q1 2018 do not represent the business they are actually running today. The question asks if management indicates that the reported period is stale relative to the operating present, with concrete things already in motion. Looking at the transcript, management discusses strong results, but also mentions several developments that are recent or ongoing. For example, they talk about the launch of iSeq, but note that they identified improvements and expect to scale shipments midyear. They mention partnerships with Loxo and BMS that are just announced, with milestones to come. They also mention the Harvard Pilgrim study and other initiatives. However, the key is whether management explicitly says that the reported numbers are behind the current business. The guidance was raised, but that's typical. The question is about a gap where the business today is ahead of the reported period. Management does say things like "we are in the earliest stages" and "we are only just beginning" but that's more about future opportunity. They also mention that the NovaSeq transition is multi-year, and that they are seeing strong demand. But do they say that the reported quarter understates the current run rate? They do mention that sequencing consumables grew strongly, and that they expect continued growth. They also mention that the pharma collaborations will contribute in the future, not in Q1. But that's typical guidance. The key is whether management repeatedly or substantially indicates that the reported period is stale. They do mention that the iSeq is in beta and will scale midyear, but that's a product launch. They also mention that the S1 flow cell launched in February and is expected to ramp. They mention that the Netherlands program is in early stages. But these are all forward-looking. The question asks: "Does management convey that the company's REPORTED RESULTS FOR THE PERIOD BEING DISCUSSED DO NOT REPRESENT THE BUSINESS THE COMPANY IS ACTUALLY RUNNING TODAY?" That is, is there a sense that the business has moved to a different level than the print? Management does not seem to say that the reported results are behind. They say results were strong, and they raised guidance. They talk about momentum, but they don't say that the quarter's numbers are not representative of the current run rate.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.